A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function in recipients treated with standard dose extended release tacrolimus alone and recipients treated with a combination of low dose extended release tacrolimus and low dose sirolimus

Trial Profile

A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function in recipients treated with standard dose extended release tacrolimus alone and recipients treated with a combination of low dose extended release tacrolimus and low dose sirolimus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Tacrolimus (Primary) ; Sirolimus
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms LOL III
  • Most Recent Events

    • 10 Mar 2015 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020 as reported by ClinicalTrials.gov.
    • 10 Mar 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov.
    • 05 Aug 2014 Planned End Date changed from 1 Oct 2016 to 1 Jun 2019 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top